2. GPCR/G Protein Neuronal Signaling Apoptosis
  3. Opioid Receptor Apoptosis
  4. (-)-P7C3-S243

(-)-P7C3-S243 is an orally active, blood-brain barrier permeable neuroprotective agent. (-)-P7C3-S243 binds to μ-opioid Receptor and TSPO. (-)-P7C3-S243 inhibits the premature apoptosis death of newborn hippocampal neurons, protects mature nigral dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment. (-)-P7C3-S243 ameliorates depression-like behaviors in rat models. (-)-P7C3-S243 is applicable to research related to Parkinson's disease and Alzheimer's disease.

For research use only. We do not sell to patients.

(-)-P7C3-S243

(-)-P7C3-S243 Chemical Structure

CAS No. : 1597443-57-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (-)-P7C3-S243:

(-)-P7C3-S243 Related Antibodies

Top Publications Citing Use of Products

View All Opioid Receptor Isoform Specific Products:

View All Isoforms
μ Opioid Receptor/MOR κ Opioid Receptor/KOR δ Opioid Receptor/DOR NOP Receptor/ORL1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(-)-P7C3-S243 is an orally active, blood-brain barrier permeable neuroprotective agent. (-)-P7C3-S243 binds to μ-opioid Receptor and TSPO. (-)-P7C3-S243 inhibits the premature apoptosis death of newborn hippocampal neurons, protects mature nigral dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment. (-)-P7C3-S243 ameliorates depression-like behaviors in rat models. (-)-P7C3-S243 is applicable to research related to Parkinson's disease and Alzheimer's disease[1][2].

In Vitro

(−)-P7C3-S243 (Compound 15) weakly inhibits CYP1A2 (IC50 = 20 μM) and CYP2C19 (IC50 = 1.9 μM) in vitro, but shows no inhibitory effect on multiple other tested CYP subtypes[1].
(−)-P7C3-S243 binds to the μ-opioid receptor (IC50 = 8.2 μM) and TSPO (IC50 = 0.35 μM) in vitro, but does not bind to most other tested neuronal receptors and channels[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(-)-P7C3-S243 Related Antibodies
In Vivo

(−)-P7C3-S243 (10 μM (12 μL/day)/0.1-10 mg/kg/day; i.c.v./i.p.; twice daily for 7 days) doubles the number of surviving newborn hippocampal neurons and improves the survival rate of hippocampal neurons in environmentally deprived mice[1]
(-)-P7C3-S243 (1-10 mg/kg; i.p.; twice daily for 21 consecutive days) dose-dependently protects mature dopaminergic neurons in the substantia nigra of mice treated with MPTP (HY-15608)[1].
(−)-P7C3-S243 (10 mg/kg; i.p.; 10 days) doubles the level of postnatal hippocampal neurogenesis in TgF344-AD rats, protects the rats from early depression-like behaviors and late cognitive impairment, reduces neurodegeneration and neuronal loss, and also ameliorates age-related depression-like behaviors in wild-type rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/J6 (12-week-old)[1]
Dosage: 10 μM; 0.1-10 mg/kg/day
Administration: i.c.v.; 0.5 μL/h; 7 days; i.p.; BID; 7 days
Result: Approximately doubled the number of surviving BrdU+ newborn hippocampal neurons compared to vehicle-treated mice.
Showed a smooth dose-response curve, with activity detectable at 1 mg/kg/day and maximum efficacy achieved at 10 mg/kg/day; efficacy reflected increased survival of newborn hippocampal neurons via neuroprotection (not increased proliferation).
Animal Model: C57Bl/6 (adult male; MPTP-induced Parkinson's disease)[1]
Dosage: 1, 3, 5, 10 mg/kg/day
Administration: i.p.; BID; 21 days
Result: Showed significant neuroprotective activity at 1 mg/kg/day, and at the highest tested dose of 10 mg/kg/day, rescued over 85% of TH+ dopaminergic neurons in the substantia nigra (compared to MPTP-treated vehicle controls).; Demonstrated higher efficacy than that of P7C3-A20, with strict enantiomeric specificity (only the (−)-S enantiomer was active).
Animal Model: Fischer 344 rats (male and female, 6 months old at treatment initiation; TgF344-AD transgenic overexpressing human mutant APP_SW and PS1ΔE9 genes; wild-type)[2]
Dosage: 10 mg/kg/d
Administration: daily; 9 months (15-month assessments); 18 months (24-month assessments)
Result: Reduced time spent immobile in the Porsolt forced swim test in TgF344-AD rats to levels comparable to WT animals at 15 months.
Did not affect locomotor activity or cause cognitive deficits in any group at 15 months.
Improved performance in the Morris water maze reversal memory probe in TgF344-AD rats, reducing time to locate the target position to levels similar to WT animals at 24 months.
Ameliorated depression-like behavior in 24-month-old WT rats, reducing time spent immobile in the Porsolt forced swim test from mean 45 seconds to mean 20 seconds (p=0.0176), but did not correct depression-like behavior in 24-month-old TgF344-AD rats.
Significantly reduced vacuole formation in the hippocampus and cerebral cortex of TgF344-AD rats at 24 months.
Prevented neuronal cell loss in the hippocampus and cerebral cortex, and increased neuronal cell counts in the dentate gyrus granule cell layer of TgF344-AD rats at 24 months.
Did not alter amyloid plaque deposition, levels of soluble or insoluble Aβ1-40/Aβ1-42 peptides, tau hyperphosphorylation (Tau PS199/202), or glial activation (GFAP+ astrocytes or Iba1+ microglia) in TgF344-AD rats at 24 months.
Molecular Weight

507.19

Formula

C21H18Br2FN3O
CAS No.
SMILES

F[C@@H](CNC1=NC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=C2C=CC(Br)=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(-)-P7C3-S243 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(-)-P7C3-S2431597443-57-6Opioid ReceptorApoptosisneuroprotective agentParkinson's diseaseAlzheimer's diseaseC57BL/J6 miceFischer 344 ratsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(-)-P7C3-S243
Cat. No.:
HY-186105A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.